Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 865-870

  Parkin, Neil T ^a   Lie, Yolanda S ^a   Hellmann, Nicholas ^a   Markowitz, Martin ^b   Bonhoeffer, Sebastian ^b   Ho, David D ^b   Petropoulos, Christos J ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; DIDANOSINE; DNA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV-1; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; PHENOTYPE; SALVAGE THERAPY; TIME FACTORS; TRANSFECTION; TREATMENT FAILURE; ZIDOVUDINE;

EID: 0032824724     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314928     Document Type: Article

References (15)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. JAMA 1998;280:78-86.
2. 2. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998;279:1984-91.
3. 3. Markowitz M, Vesanen MS, Cao Y, et al. Variable suppression of HIV-1 replication in patients treated with nelfinavir in combination with AZT and 3TC for greater than two years [abstract 22400]. In: Program and abstracts: 12th World AIDS Conference (Geneva). Stockholm: International AIDS Society, 1998.
4. 4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91.
5. 5. Meijer A, van Loon AM, Borleffs JCC, Roozendaal G. Development of molecular methods for detection and epidemiological investigation of HIV-1, HIV-2, and HTLV I/II infections. Bilthoven, Netherlands: National Institute of Public Health and Environmental Protection, 1995.
6. 6. Landau NR, Page KA, Littman DR. Pseudotyping with human T-cell leukemia virus type 1 broadens the human immunodeficiency virus host range. J Virol 1991;65:162-9.
7. 7. Efron B, Tibshirani RJ. An introduction to the bootstrap. Monogr Stat Appl Probability 1994:45-59.
8. 8. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk, CT: Appleton & Lange, 1993.
9. 9. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;7:46-69.
10. 10. Kern D, Collins M, Fultz T, et al. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996;34:3196-202.
11. 11. Collins M, Irvine B, Tyner D, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/mL. Nucleic Acids Res 1997;25:2979-85.
12. 12. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997;35:1278-80.
13. 13. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998;42:2637-44.
14. 14. Havlir DV, Petropoulos CJ, Hellman NS, Whitcomb JM, Richman DD. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine [abstract 74]. In: Program and abstracts: 2nd International Workshop on HIV Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). London, England: International Medical Press, 1998.
15. 15. McLean AR, Emery VC, Webster A, Grifliths PD. Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 1991; 5:485-9.